valine and deoxycytidine

valine has been researched along with deoxycytidine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, M; Lin, K; Liu, Q; Villareal, VA; Yang, PL1
Chatterjee, A; Perelson, AS; Smith, PF1
Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S1
Cotler, SJ; Dahari, H; Guedj, J; Layden, TJ; Nettles, RE; Perelson, AS; Rong, L; Sansone, ND; Uprichard, SL1
Cha, H; Cho, WJ; Dung, le TK; Lee, HY; Lee, SJ; Min, YJ; Moon, CH; Park, JW1

Reviews

2 review(s) available for valine and deoxycytidine

ArticleYear
Anti-HCV drugs in the pipeline.
    Current opinion in virology, 2011, Volume: 1, Issue:6

    Topics: Animals; Antiviral Agents; Carbamates; Cyclosporine; Deoxycytidine; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication

2011
Hepatitis C viral kinetics: the past, present, and future.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, Biological; Oligopeptides; Protease Inhibitors; Pyrrolidines; Silybin; Silymarin; Valine

2013

Other Studies

3 other study(ies) available for valine and deoxycytidine

ArticleYear
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Cancer letters, 2013, Jul-10, Volume: 335, Issue:1

    Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays

2013
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Mar-05, Volume: 110, Issue:10

    Topics: Adult; Antiviral Agents; Bayes Theorem; Carbamates; Cell Line; Deoxycytidine; Female; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Models, Biological; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins; Virus Assembly

2013
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
    Investigational new drugs, 2014, Volume: 32, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzophenones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Mice, Mutant Strains; Microtubules; Neoplasms; Neovascularization, Pathologic; Tubulin; Tumor Burden; Valine; Xenograft Model Antitumor Assays

2014